BiotechTube
Home/Maze Therapeutics/Mark Boshar
MB

Mark Boshar

Chief Financial Officer

Maze Therapeutics

Therapeutic Areas

RenalMetabolicNeuromuscularRare Diseases

Maze Therapeutics Pipeline

DrugIndicationPhase
MZE001APOL1-Mediated Kidney Disease (AMKD)Phase 2
Undisclosed ProgramPompe Disease (GAA Deficiency)Preclinical

Leadership Team at Maze Therapeutics

JC
Jason Coloma, Ph.D.
President and Chief Executive Officer
WH
William H. Rastetter, Ph.D.
Chairman of the Board
HB
Harold Bernstein, M.D., Ph.D.
Chief Medical Officer
MM
Mark Murcko, Ph.D.
Chief Scientific Advisor
CH
Charles Homcy, M.D.
Co-Founder and Board Director
DG
David Goldstein, Ph.D.
Co-Founder and Board Observer
AB
Atul Butte, M.D., Ph.D.
Co-Founder and Board Observer
KE
Kathryn E. Giusti
Board Director
BZ
Brett Zbar, M.D.
Board Director
SA
Santiago Arroyo, M.D., Ph.D.
Board Director (Partner at SR One)
View full Maze Therapeutics profile